Literature DB >> 1243674

Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells.

D Niethammer, R C Jackson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1243674     DOI： 10.1016/0014-2964(75)90083-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  14 in total

1.  Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

Authors:  M Khorsand; J Lange; L Feun; N J Clendeninn; M Collier; G Wilding
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.

Authors:  R G Moran; M Mulkins; C Heidelberger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  Use of the circuit simulation program SPICE2 for analysis of the metabolism of anticancer drugs.

Authors:  J C White
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

5.  Mutations in the reduced-folate carrier affect protein localization and stability.

Authors:  H Sadlish; R C Murray; F M Williams; W F Flintoff
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

6.  Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

Authors:  S Cabral; S Leis; L Bover; M Nembrot; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

7.  Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles.

Authors:  C H Yang; M Dembo; F M Sirotnak
Journal:  J Membr Biol       Date:  1983       Impact factor: 1.843

8.  Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia.

Authors:  A Ramu; M Fridkin; R Steinherz
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  High-dose methotrexate therapy with leucovorin rescue: in vitro investigations on human osteosarcoma cell lines.

Authors:  H Diddens; T Teufel; D Niethammer
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Interactions between inhibitors of dihydrofolate reductase.

Authors:  K Bowden; A D Hall; B Birdsall; J Feeney; G C Roberts
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.